25 XP   0   0   10

10X Genomics Inc
Buy, Hold or Sell?

Let's analyse 10X Genomics Inc together

PenkeI guess you are interested in 10X Genomics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of 10X Genomics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about 10X Genomics Inc

I send you an email if I find something interesting about 10X Genomics Inc.

Quick analysis of 10X Genomics Inc (30 sec.)










What can you expect buying and holding a share of 10X Genomics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.25
Expected worth in 1 year
$5.48
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
$-0.77
Return On Investment
-2.1%

For what price can you sell your share?

Current Price per Share
$36.89
Expected price per share
$31.28 - $48.42
How sure are you?
50%

1. Valuation of 10X Genomics Inc (5 min.)




Live pricePrice per Share (EOD)

$36.89

Intrinsic Value Per Share

$67.04 - $81.24

Total Value Per Share

$73.29 - $87.49

2. Growth of 10X Genomics Inc (5 min.)




Is 10X Genomics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$741m$792.9m-$22.4m-2.9%

How much money is 10X Genomics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$63.7m-$41.5m-$22.2m-34.9%
Net Profit Margin-41.9%-34.1%--

How much money comes from the company's main activities?

3. Financial Health of 10X Genomics Inc (5 min.)




4. Comparing to competitors in the Health Information Services industry (5 min.)




  Industry Rankings (Health Information Services)  


Richest
#17 / 122

Most Revenue
#24 / 122

Most Profit
#117 / 122

What can you expect buying and holding a share of 10X Genomics Inc? (5 min.)

Welcome investor! 10X Genomics Inc's management wants to use your money to grow the business. In return you get a share of 10X Genomics Inc.

What can you expect buying and holding a share of 10X Genomics Inc?

First you should know what it really means to hold a share of 10X Genomics Inc. And how you can make/lose money.

Speculation

The Price per Share of 10X Genomics Inc is $36.89. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of 10X Genomics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in 10X Genomics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.25. Based on the TTM, the Book Value Change Per Share is $-0.19 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of 10X Genomics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.41-1.1%-0.54-1.5%-0.37-1.0%-0.48-1.3%-0.43-1.2%
Usd Book Value Change Per Share-0.08-0.2%-0.19-0.5%-0.07-0.2%0.421.1%0.260.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.08-0.2%-0.19-0.5%-0.07-0.2%0.421.1%0.260.7%
Usd Price Per Share55.96-52.21-46.56-80.55-67.13-
Price to Earnings Ratio-33.88--26.21--37.67--112.12--93.44-
Price-to-Total Gains Ratio-700.34--466.43--191.76--34.85--34.85-
Price to Book Ratio8.95-7.93-6.65-13.03-10.86-
Price-to-Total Gains Ratio-700.34--466.43--191.76--34.85--34.85-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share36.89
Number of shares27
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.190.42
Usd Total Gains Per Share-0.190.42
Gains per Quarter (27 shares)-5.2111.26
Gains per Year (27 shares)-20.8245.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-21-3104535
20-42-5209080
30-62-730135125
40-83-940180170
50-104-1150225215
60-125-1360270260
70-146-1570315305
80-167-1780360350
90-187-1990405395
100-208-2200451440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.024.00.00.0%0.024.00.00.0%
Book Value Change Per Share0.04.00.00.0%5.07.00.041.7%8.011.01.040.0%9.012.03.037.5%9.012.03.037.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.024.00.0%0.00.024.00.0%
Total Gains per Share0.04.00.00.0%5.07.00.041.7%8.011.01.040.0%9.012.03.037.5%9.012.03.037.5%

Fundamentals of 10X Genomics Inc

About 10X Genomics Inc

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Fundamental data was last updated by Penke on 2024-03-18 15:02:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of 10X Genomics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit 10X Genomics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare 10X Genomics Inc to the Health Information Services industry mean.
  • A Net Profit Margin of -26.6% means that $-0.27 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of 10X Genomics Inc:

  • The MRQ is -26.6%. The company is making a huge loss. -2
  • The TTM is -41.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-26.6%TTM-41.9%+15.2%
TTM-41.9%YOY-34.1%-7.8%
TTM-41.9%5Y-49.4%+7.5%
5Y-49.4%10Y-51.4%+2.0%
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.6%-18.8%-7.8%
TTM-41.9%-21.3%-20.6%
YOY-34.1%-28.1%-6.0%
5Y-49.4%-32.6%-16.8%
10Y-51.4%-41.1%-10.3%
1.1.2. Return on Assets

Shows how efficient 10X Genomics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare 10X Genomics Inc to the Health Information Services industry mean.
  • -5.1% Return on Assets means that 10X Genomics Inc generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of 10X Genomics Inc:

  • The MRQ is -5.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.1%TTM-6.5%+1.5%
TTM-6.5%YOY-4.1%-2.4%
TTM-6.5%5Y-6.1%-0.4%
5Y-6.1%10Y-8.2%+2.0%
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.1%-4.3%-0.8%
TTM-6.5%-5.8%-0.7%
YOY-4.1%-5.2%+1.1%
5Y-6.1%-5.8%-0.3%
10Y-8.2%-8.0%-0.2%
1.1.3. Return on Equity

Shows how efficient 10X Genomics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare 10X Genomics Inc to the Health Information Services industry mean.
  • -6.6% Return on Equity means 10X Genomics Inc generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of 10X Genomics Inc:

  • The MRQ is -6.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.6%TTM-8.3%+1.7%
TTM-8.3%YOY-5.3%-3.1%
TTM-8.3%5Y-11.6%+3.3%
5Y-11.6%10Y-11.2%-0.4%
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.6%-4.0%-2.6%
TTM-8.3%-5.9%-2.4%
YOY-5.3%-7.9%+2.6%
5Y-11.6%-7.6%-4.0%
10Y-11.2%-9.6%-1.6%

1.2. Operating Efficiency of 10X Genomics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient 10X Genomics Inc is operating .

  • Measures how much profit 10X Genomics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare 10X Genomics Inc to the Health Information Services industry mean.
  • An Operating Margin of -19.4% means the company generated $-0.19  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of 10X Genomics Inc:

  • The MRQ is -19.4%. The company is operating very inefficient. -2
  • The TTM is -42.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-19.4%TTM-42.3%+23.0%
TTM-42.3%YOY-34.2%-8.1%
TTM-42.3%5Y-30.1%-12.2%
5Y-30.1%10Y-27.0%-3.1%
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.4%-17.8%-1.6%
TTM-42.3%-11.4%-30.9%
YOY-34.2%-24.9%-9.3%
5Y-30.1%-18.8%-11.3%
10Y-27.0%-28.4%+1.4%
1.2.2. Operating Ratio

Measures how efficient 10X Genomics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Health Information Services industry mean).
  • An Operation Ratio of 1.19 means that the operating costs are $1.19 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of 10X Genomics Inc:

  • The MRQ is 1.194. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.407. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.194TTM1.407-0.214
TTM1.407YOY1.342+0.065
TTM1.4075Y1.272+0.135
5Y1.27210Y1.251+0.021
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1941.266-0.072
TTM1.4071.376+0.031
YOY1.3421.407-0.065
5Y1.2721.327-0.055
10Y1.2511.332-0.081

1.3. Liquidity of 10X Genomics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if 10X Genomics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Health Information Services industry mean).
  • A Current Ratio of 4.69 means the company has $4.69 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of 10X Genomics Inc:

  • The MRQ is 4.687. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.344. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.687TTM5.344-0.656
TTM5.344YOY5.711-0.368
TTM5.3445Y5.747-0.403
5Y5.74710Y5.063+0.684
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6871.660+3.027
TTM5.3441.735+3.609
YOY5.7112.035+3.676
5Y5.7472.603+3.144
10Y5.0632.525+2.538
1.3.2. Quick Ratio

Measures if 10X Genomics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare 10X Genomics Inc to the Health Information Services industry mean.
  • A Quick Ratio of 4.19 means the company can pay off $4.19 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of 10X Genomics Inc:

  • The MRQ is 4.191. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.944. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.191TTM4.944-0.753
TTM4.944YOY6.838-1.894
TTM4.9445Y5.587-0.643
5Y5.58710Y4.816+0.771
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1911.121+3.070
TTM4.9441.186+3.758
YOY6.8381.695+5.143
5Y5.5871.953+3.634
10Y4.8161.898+2.918

1.4. Solvency of 10X Genomics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of 10X Genomics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare 10X Genomics Inc to Health Information Services industry mean.
  • A Debt to Asset Ratio of 0.23 means that 10X Genomics Inc assets are financed with 23.2% credit (debt) and the remaining percentage (100% - 23.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of 10X Genomics Inc:

  • The MRQ is 0.232. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.213. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.232TTM0.213+0.019
TTM0.213YOY0.213+0.000
TTM0.2135Y0.391-0.177
5Y0.39110Y0.475-0.084
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2320.428-0.196
TTM0.2130.430-0.217
YOY0.2130.397-0.184
5Y0.3910.414-0.023
10Y0.4750.446+0.029
1.4.2. Debt to Equity Ratio

Measures if 10X Genomics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare 10X Genomics Inc to the Health Information Services industry mean.
  • A Debt to Equity ratio of 30.2% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of 10X Genomics Inc:

  • The MRQ is 0.302. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.272. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.302TTM0.272+0.031
TTM0.272YOY0.271+0.001
TTM0.2725Y1.472-1.201
5Y1.47210Y1.227+0.245
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3020.610-0.308
TTM0.2720.616-0.344
YOY0.2710.651-0.380
5Y1.4720.715+0.757
10Y1.2270.671+0.556

2. Market Valuation of 10X Genomics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings 10X Genomics Inc generates.

  • Above 15 is considered overpriced but always compare 10X Genomics Inc to the Health Information Services industry mean.
  • A PE ratio of -33.88 means the investor is paying $-33.88 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of 10X Genomics Inc:

  • The EOD is -22.338. Based on the earnings, the company is expensive. -2
  • The MRQ is -33.885. Based on the earnings, the company is expensive. -2
  • The TTM is -26.206. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-22.338MRQ-33.885+11.547
MRQ-33.885TTM-26.206-7.679
TTM-26.206YOY-37.675+11.469
TTM-26.2065Y-112.124+85.919
5Y-112.12410Y-93.437-18.687
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
EOD-22.338-1.288-21.050
MRQ-33.885-1.437-32.448
TTM-26.206-1.650-24.556
YOY-37.675-3.185-34.490
5Y-112.124-6.094-106.030
10Y-93.437-5.971-87.466
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of 10X Genomics Inc:

  • The EOD is 49.017. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 74.356. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -42.761. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD49.017MRQ74.356-25.339
MRQ74.356TTM-42.761+117.117
TTM-42.761YOY-32.695-10.066
TTM-42.7615Y846.712-889.473
5Y846.71210Y705.593+141.119
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
EOD49.017-1.899+50.916
MRQ74.356-2.501+76.857
TTM-42.761-3.132-39.629
YOY-32.695-5.389-27.306
5Y846.712-6.141+852.853
10Y705.593-6.517+712.110
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of 10X Genomics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Health Information Services industry mean).
  • A PB ratio of 8.95 means the investor is paying $8.95 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of 10X Genomics Inc:

  • The EOD is 5.902. Based on the equity, the company is overpriced. -1
  • The MRQ is 8.954. Based on the equity, the company is overpriced. -1
  • The TTM is 7.931. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.902MRQ8.954-3.051
MRQ8.954TTM7.931+1.022
TTM7.931YOY6.648+1.283
TTM7.9315Y13.028-5.097
5Y13.02810Y10.857+2.171
Compared to industry (Health Information Services)
PeriodCompanyIndustry (mean)+/- 
EOD5.9021.495+4.407
MRQ8.9541.692+7.262
TTM7.9311.838+6.093
YOY6.6482.891+3.757
5Y13.0284.349+8.679
10Y10.8574.177+6.680
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of 10X Genomics Inc.

3.1. Institutions holding 10X Genomics Inc

Institutions are holding 92.505% of the shares of 10X Genomics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31FMR Inc10.72910.055127855361185380.9358
2023-12-31Vanguard Group Inc7.5620.01190113321078151.2109
2023-12-31Baillie Gifford & Co Limited.6.64610.35127919976-420922-5.0465
2023-12-31BlackRock Inc4.78770.008157053922190983.9936
2023-12-31Morgan Stanley - Brokerage Accounts3.50720.02064179415-170635-3.9226
2023-12-31ARK Investment Management LLC3.39131.33894041287104782735.0039
2023-12-31Sands Capital Management, LLC3.01270.61063590145-395325-9.9192
2023-12-31Brown Capital Management, LLC2.962.9617352729744619214.4816
2023-12-31T. Rowe Price Associates, Inc.2.60490.0233310417441672315.5063
2023-12-31Amvescap Plc.1.95940.031123349381084724.8719
2023-12-31Nikko Asset Management Americas Inc1.91631.2282228353056505932.8815
2023-12-31Sumitomo Mitsui Trust Holdings Inc1.91630.0945228353056505932.8815
2023-12-31Venrock Management VI LLC1.767910021067571144448118.9273
2023-12-31Geode Capital Management, LLC1.33240.00931587815687714.5273
2023-12-31State Street Corporation1.30840.00421559228985916.7499
2023-12-31RTW INVESTMENTS, LLC1.30071.35481549951299951.9734
2023-12-31Generation Investment Management LLP1.28510.38851531392-7436-0.4832
2023-12-31JPMorgan Chase & Co1.2380.0079147528624312419.7315
2023-12-31BP WEALTH MANAGEMENT, LLC1.21391.9692144655269342292.072
2023-09-30Point72 Asset Management, L.P.1.13070.16221347419-255749-15.9527
Total 61.5701110.630373370952+4623067+6.3%

3.2. Funds holding 10X Genomics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29ARK Innovation ETF3.33762.2594397731879280.1997
2024-01-31Vanguard Total Stock Mkt Idx Inv2.46410.0083293639548560.1656
2023-12-31ARK Disruptive Innovation Full Composite2.27451.6339271048270026034.835
2024-01-31Vanguard Small Cap Index2.00870.0755239373066210.2774
2024-01-31Fidelity Select Health Care1.96361.2749234000000
2024-01-31Fidelity Select Medical Tech and Devcs1.91191.6498227828811000.0483
2024-01-31Fidelity Growth Company Fund1.79440.16252138292-1360-0.0636
2023-12-31Sands Capital Select Growth TE Inst EQ1.74871.5151208391619379941328.1027
2023-12-31Scottish Mortgage Ord1.49990.5811787427-328-0.0183
2023-09-30Brown Capital Mgmt Small Co Inv1.38741.9925165326500
2024-01-31Fidelity Advisor Health Care I1.33961.37715963068060.0505
2024-01-31Nikko AM ARK Disruptive Innovation A USD1.33852.3699159504126014119.4877
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr1.29380.06681541722-967-0.0627
2024-02-29ARK Genomic Revolution ETF1.27263.78251516502119570.7947
2023-12-31T. Rowe Price Health Sciences1.18660.5379141405619003615.5256
2024-01-31CS (Lux) Digital Health Equity SB USD1.17483.8614140000027000023.8938
2024-01-31Fidelity Growth Compy Commingled Pl O1.17230.08121397030162701.1783
2024-01-31Baillie Gifford US Equity Growth1.13430.7331135176100
2023-12-31Vanguard US Growth Investor1.13430.189135176100
2024-01-31Vanguard Small Cap Growth Index Inv1.12130.1744133616826410.198
Total 32.558924.326138799460+3407955+8.8%

3.3. Insider Transactions

Insiders are holding 2.264% of the shares of 10X Genomics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-04Serge SaxonovSELL466044
2024-02-22Benjamin J HindsonSELL261346.34
2024-02-22Justin J McanearSELL186546.34
2024-02-22Serge SaxonovSELL282146.34
2024-02-09Serge SaxonovSELL100049.53
2024-01-16Serge SaxonovSELL400045.24
2023-12-14Serge SaxonovSELL200055.03
2023-11-24Serge SaxonovSELL372343.72
2023-11-22James WilburSELL346443.34
2023-11-22Justin J McanearSELL167943.34
2023-11-22Serge SaxonovSELL375743.34
2023-11-20James WilburSELL1471842.09
2023-10-16Serge SaxonovSELL2139.5
2023-09-14Serge SaxonovSELL200049.37
2023-08-22Justin J McanearSELL167845.78
2023-08-22Serge SaxonovSELL375745.78
2023-08-22James WilburSELL969945.78
2023-08-14Serge SaxonovSELL200050.11
2023-08-01Benjamin J HindsonSELL697062.21
2023-07-19Benjamin J HindsonSELL1394060.03

4. Summary

4.1. Key Performance Indicators

The key performance indicators of 10X Genomics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.080-0.193+141%-0.071-11%0.417-119%0.260-131%
Book Value Per Share--6.2506.579-5%6.965-10%5.558+12%4.554+37%
Current Ratio--4.6875.344-12%5.711-18%5.747-18%5.063-7%
Debt To Asset Ratio--0.2320.213+9%0.213+9%0.391-41%0.475-51%
Debt To Equity Ratio--0.3020.272+11%0.271+12%1.472-79%1.227-75%
Dividend Per Share----0%-0%-0%-0%
Eps---0.413-0.544+32%-0.365-12%-0.477+16%-0.428+4%
Free Cash Flow Per Share--0.188-0.139+174%-0.363+293%-0.280+249%-0.267+242%
Free Cash Flow To Equity Per Share--0.235-0.110+147%-0.329+240%0.169+40%0.149+58%
Gross Profit Margin--1.0001.0000%1.054-5%1.011-1%1.010-1%
Intrinsic Value_10Y_max--81.240--------
Intrinsic Value_10Y_min--67.044--------
Intrinsic Value_1Y_max--0.289--------
Intrinsic Value_1Y_min--0.279--------
Intrinsic Value_3Y_max--6.852--------
Intrinsic Value_3Y_min--6.421--------
Intrinsic Value_5Y_max--20.630--------
Intrinsic Value_5Y_min--18.633--------
Market Cap3877507900.000-71%6634937915.0406114654724.320+9%5291070711.753+25%8859220803.542-25%7382684002.951-10%
Net Profit Margin---0.266-0.419+57%-0.341+28%-0.494+86%-0.514+93%
Operating Margin---0.194-0.423+119%-0.342+77%-0.301+56%-0.270+40%
Operating Ratio--1.1941.407-15%1.342-11%1.272-6%1.251-5%
Pb Ratio5.902-52%8.9547.931+13%6.648+35%13.028-31%10.857-18%
Pe Ratio-22.338+34%-33.885-26.206-23%-37.675+11%-112.124+231%-93.437+176%
Price Per Share36.890-52%55.96052.210+7%46.560+20%80.550-31%67.125-17%
Price To Free Cash Flow Ratio49.017-52%74.356-42.761+158%-32.695+144%846.712-91%705.593-89%
Price To Total Gains Ratio-461.677+34%-700.338-466.428-33%-191.756-73%-34.853-95%-34.853-95%
Quick Ratio--4.1914.944-15%6.838-39%5.587-25%4.816-13%
Return On Assets---0.051-0.065+29%-0.041-18%-0.061+21%-0.082+61%
Return On Equity---0.066-0.083+26%-0.053-20%-0.116+76%-0.112+69%
Total Gains Per Share---0.080-0.193+141%-0.071-11%0.417-119%0.260-131%
Usd Book Value--741043000.000770486250.000-4%792934000.000-7%620492250.000+19%508879791.667+46%
Usd Book Value Change Per Share---0.080-0.193+141%-0.071-11%0.417-119%0.260-131%
Usd Book Value Per Share--6.2506.579-5%6.965-10%5.558+12%4.554+37%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.413-0.544+32%-0.365-12%-0.477+16%-0.428+4%
Usd Free Cash Flow--22308000.000-16180250.000+173%-41316750.000+285%-30853550.000+238%-29174541.667+231%
Usd Free Cash Flow Per Share--0.188-0.139+174%-0.363+293%-0.280+249%-0.267+242%
Usd Free Cash Flow To Equity Per Share--0.235-0.110+147%-0.329+240%0.169+40%0.149+58%
Usd Market Cap3877507900.000-71%6634937915.0406114654724.320+9%5291070711.753+25%8859220803.542-25%7382684002.951-10%
Usd Price Per Share36.890-52%55.96052.210+7%46.560+20%80.550-31%67.125-17%
Usd Profit---48952000.000-63774750.000+30%-41500000.000-15%-52665150.000+8%-48370958.333-1%
Usd Revenue--183979000.000154681750.000+19%129102250.000+43%108518200.000+70%96618541.667+90%
Usd Total Gains Per Share---0.080-0.193+141%-0.071-11%0.417-119%0.260-131%
 EOD+4 -4MRQTTM+22 -11YOY+12 -225Y+22 -1210Y+21 -13

4.2. Fundamental Score

Let's check the fundamental score of 10X Genomics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-22.338
Price to Book Ratio (EOD)Between0-15.902
Net Profit Margin (MRQ)Greater than0-0.266
Operating Margin (MRQ)Greater than0-0.194
Quick Ratio (MRQ)Greater than14.191
Current Ratio (MRQ)Greater than14.687
Debt to Asset Ratio (MRQ)Less than10.232
Debt to Equity Ratio (MRQ)Less than10.302
Return on Equity (MRQ)Greater than0.15-0.066
Return on Assets (MRQ)Greater than0.05-0.051
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of 10X Genomics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.238
Ma 20Greater thanMa 5039.448
Ma 50Greater thanMa 10042.837
Ma 100Greater thanMa 20044.919
OpenGreater thanClose36.880
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets965,143
Total Liabilities224,100
Total Stockholder Equity741,043
 As reported
Total Liabilities 224,100
Total Stockholder Equity+ 741,043
Total Assets = 965,143

Assets

Total Assets965,143
Total Current Assets596,022
Long-term Assets369,121
Total Current Assets
Cash And Cash Equivalents 359,284
Short-term Investments 29,411
Net Receivables 114,832
Inventory 73,706
Other Current Assets 18,789
Total Current Assets  (as reported)596,022
Total Current Assets  (calculated)596,022
+/-0
Long-term Assets
Property Plant Equipment 344,932
Goodwill 4,511
Intangible Assets 16,616
Long-term Assets Other 3,062
Long-term Assets  (as reported)369,121
Long-term Assets  (calculated)369,121
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities127,162
Long-term Liabilities96,938
Total Stockholder Equity741,043
Total Current Liabilities
Short-term Debt 11,521
Accounts payable 15,738
Other Current Liabilities 86,753
Total Current Liabilities  (as reported)127,162
Total Current Liabilities  (calculated)114,012
+/- 13,150
Long-term Liabilities
Capital Lease Obligations 95,370
Long-term Liabilities  (as reported)96,938
Long-term Liabilities  (calculated)95,370
+/- 1,568
Total Stockholder Equity
Common Stock2
Retained Earnings -1,284,420
Accumulated Other Comprehensive Income -429
Other Stockholders Equity 2,025,890
Total Stockholder Equity (as reported)741,043
Total Stockholder Equity (calculated)741,043
+/-0
Other
Capital Stock2
Cash and Short Term Investments 388,695
Common Stock Shares Outstanding 118,566
Current Deferred Revenue13,150
Liabilities and Stockholders Equity 965,143
Net Debt -263,914
Net Invested Capital 741,043
Net Working Capital 468,860
Property Plant and Equipment Gross 448,423
Short Long Term Debt Total 95,370



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
124,310
124,310
0
155,594
572,815
605,923
610,384
582,802
1,042,544
929,341
954,033
977,579
990,572
1,018,826
1,003,251
1,001,591
996,207
1,028,980
1,014,030
989,638
948,540
965,143
965,143948,540989,6381,014,0301,028,980996,2071,001,5911,003,2511,018,826990,572977,579954,033929,3411,042,544582,802610,384605,923572,815155,5940124,310124,31000
   > Total Current Assets 
47,857
0
106,236
106,236
65,080
107,226
474,144
480,840
429,732
451,584
900,451
774,366
745,716
757,174
744,104
747,591
697,335
666,232
629,422
635,035
601,894
582,940
562,348
596,022
596,022562,348582,940601,894635,035629,422666,232697,335747,591744,104757,174745,716774,366900,451451,584429,732480,840474,144107,22665,080106,236106,236047,857
       Cash And Cash Equivalents 
-47,857
0
65,080
65,080
-65,080
56,034
427,436
424,166
372,428
339,840
768,773
663,603
617,195
621,958
600,440
587,447
312,487
274,187
233,951
219,746
332,320
325,879
311,264
359,284
359,284311,264325,879332,320219,746233,951274,187312,487587,447600,440621,958617,195663,603768,773339,840372,428424,166427,43656,034-65,08065,08065,0800-47,857
       Short-term Investments 
95,714
0
0
0
130,160
0
0
0
0
0
0
0
0
0
0
0
226,836
225,546
218,435
210,238
85,970
65,506
45,643
29,411
29,41145,64365,50685,970210,238218,435225,546226,83600000000000130,16000095,714
       Net Receivables 
0
0
29,566
29,566
0
34,747
26,150
33,371
30,851
22,726
36,026
51,208
57,408
59,680
78,430
85,254
76,526
76,204
83,549
104,211
77,940
87,685
103,847
114,832
114,832103,84787,68577,940104,21183,54976,20476,52685,25478,43059,68057,40851,20836,02622,72630,85133,37126,15034,747029,56629,56600
       Other Current Assets 
0
0
0
3,020
0
4,120
7,253
8,033
7,096
9,411
11,083
13,029
14,442
13,298
14,065
13,896
17,789
19,649
14,858
16,578
20,857
18,683
20,177
18,789
18,78920,17718,68320,85716,57814,85819,64917,78913,89614,06513,29814,44213,02911,0839,4117,0968,0337,2534,12003,020000
   > Long-term Assets 
0
0
0
18,074
0
48,368
98,671
125,083
180,652
131,218
142,093
154,975
208,317
220,405
246,468
271,235
305,916
335,359
366,785
393,945
412,136
406,698
386,192
369,121
369,121386,192406,698412,136393,945366,785335,359305,916271,235246,468220,405208,317154,975142,093131,218180,652125,08398,67148,368018,074000
       Property Plant Equipment 
0
0
11,127
11,127
0
38,337
46,840
48,821
96,432
99,067
110,490
119,823
163,666
176,454
203,304
230,410
265,880
296,426
328,789
359,210
366,844
355,962
354,200
344,932
344,932354,200355,962366,844359,210328,789296,426265,880230,410203,304176,454163,666119,823110,49099,06796,43248,82146,84038,337011,12711,12700
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
4,511
4,511
4,511
4,511
4,511
4,511
4,511
4,511
4,511
4,511
4,511
4,511
4,5114,5114,5114,5114,5114,5114,5114,5114,5114,5114,5114,511000000000000
       Intangible Assets 
0
0
400
400
0
400
0
400
0
0
21,929
22,354
27,342
26,693
26,041
25,397
24,764
24,128
23,493
22,858
22,948
22,290
21,833
16,616
16,61621,83322,29022,94822,85823,49324,12824,76425,39726,04126,69327,34222,35421,929004000400040040000
       Other Assets 
0
0
6,547
6,547
0
9,631
51,831
75,862
84,220
10,600
9,674
82,135
40,140
39,440
38,653
10,917
10,761
10,294
9,992
7,366
17,833
23,935
5,648
0
05,64823,93517,8337,3669,99210,29410,76110,91738,65339,44040,14082,1359,67410,60084,22075,86251,8319,63106,5476,54700
> Total Liabilities 
0
0
101,053
344,297
0
140,298
151,367
185,840
201,316
191,533
217,464
190,269
201,573
192,993
190,351
201,258
196,566
218,075
220,415
223,237
211,645
196,337
203,324
224,100
224,100203,324196,337211,645223,237220,415218,075196,566201,258190,351192,993201,573190,269217,464191,533201,316185,840151,367140,2980344,297101,05300
   > Total Current Liabilities 
0
0
32,362
32,362
0
43,227
48,236
63,049
59,068
122,180
145,571
118,126
120,549
113,126
100,375
110,357
94,446
117,908
126,855
130,957
112,006
98,087
104,717
127,162
127,162104,71798,087112,006130,957126,855117,90894,446110,357100,375113,126120,549118,126145,571122,18059,06863,04948,23643,227032,36232,36200
       Short-term Debt 
0
0
0
4,187
0
4,887
7,383
9,882
3,453
3,938
4,976
5,936
6,156
4,905
4,464
5,131
7,637
7,977
8,393
9,037
9,199
9,286
10,005
11,521
11,52110,0059,2869,1999,0378,3937,9777,6375,1314,4644,9056,1565,9364,9763,9383,4539,8827,3834,88704,187000
       Short Long Term Debt 
0
0
4,187
4,187
0
4,887
7,383
9,882
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000009,8827,3834,88704,1874,18700
       Accounts payable 
0
0
8,792
8,792
0
9,429
11,959
13,028
13,505
9,916
9,490
4,709
15,578
16,181
17,037
17,351
18,956
26,731
21,594
21,599
29,317
23,124
18,836
15,738
15,73818,83623,12429,31721,59921,59426,73118,95617,35117,03716,18115,5784,7099,4909,91613,50513,02811,9599,42908,7928,79200
       Other Current Liabilities 
0
0
8,255
16,607
0
25,675
25,812
36,842
38,716
104,894
127,330
103,009
94,334
86,766
73,369
82,535
62,419
76,727
90,203
92,454
64,960
56,460
64,733
86,753
86,75364,73356,46064,96092,45490,20376,72762,41982,53573,36986,76694,334103,009127,330104,89438,71636,84225,81225,675016,6078,25500
   > Long-term Liabilities 
0
0
0
311,935
0
97,071
103,131
122,791
142,248
69,353
71,893
72,143
81,024
79,867
89,976
90,901
102,120
100,167
93,560
92,280
99,639
98,250
98,607
96,938
96,93898,60798,25099,63992,28093,560100,167102,12090,90189,97679,86781,02472,14371,89369,353142,248122,791103,13197,0710311,935000
       Long term Debt Total 
0
0
0
0
0
24,777
22,307
19,837
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000019,83722,30724,77700000
       Other Liabilities 
0
0
43,202
43,202
0
72,294
80,824
102,954
86,082
14,125
15,275
15,101
14,680
13,950
14,241
14,054
8,582
9,127
5,727
6,141
6,796
7,919
10,139
0
010,1397,9196,7966,1415,7279,1278,58214,05414,24113,95014,68015,10115,27514,12586,082102,95480,82472,294043,20243,20200
> Total Stockholder Equity
45,905
0
-219,987
-219,987
23,257
15,296
421,448
420,083
409,068
391,269
825,080
739,072
752,460
784,586
800,221
817,568
806,685
783,516
775,792
805,743
802,385
793,301
745,216
741,043
741,043745,216793,301802,385805,743775,792783,516806,685817,568800,221784,586752,460739,072825,080391,269409,068420,083421,44815,29623,257-219,987-219,987045,905
   Retained Earnings -1,284,420-1,235,468-1,142,482-1,080,068-1,029,321-1,012,106-970,192-905,734-863,321-844,872-827,701-816,649-805,098-389,525-323,677-283,510-262,367-255,233-245,6300-231,116-231,11600
   Accumulated Other Comprehensive Income 
0
0
0
-37
0
-34
-160
-46
-41
314
-52
-50
48
58
194
22
-2,443
-3,965
-5,492
-4,335
-1,479
-969
-677
-429
-429-677-969-1,479-4,335-5,492-3,965-2,443221945848-50-52314-41-46-160-340-37000
   Capital Surplus 
0
0
0
0
0
17,715
676,839
682,494
692,617
0
0
1,544,218
1,569,059
1,612,227
1,644,897
1,680,865
1,714,860
1,757,671
1,793,388
1,839,397
1,883,930
1,936,750
0
0
001,936,7501,883,9301,839,3971,793,3881,757,6711,714,8601,680,8651,644,8971,612,2271,569,0591,544,21800692,617682,494676,83917,71500000
   Treasury Stock000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue618,727
Cost of Revenue-209,414
Gross Profit409,313409,313
 
Operating Income (+$)
Gross Profit409,313
Operating Expense-611,181
Operating Income-201,868-201,868
 
Operating Expense (+$)
Research Development270,332
Selling General Administrative343,330
Selling And Marketing Expenses0
Operating Expense611,181613,662
 
Net Interest Income (+$)
Interest Income16,906
Interest Expense-33
Other Finance Cost-0
Net Interest Income16,873
 
Pretax Income (+$)
Operating Income-201,868
Net Interest Income16,873
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-248,763-154,973
EBIT - interestExpense = -201,901
-248,763
-255,066
Interest Expense33
Earnings Before Interest and Taxes (EBIT)-201,868-248,730
Earnings Before Interest and Taxes (EBITDA)-158,249
 
After tax Income (+$)
Income Before Tax-248,763
Tax Provision-6,336
Net Income From Continuing Ops-255,099-255,099
Net Income-255,099
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses820,595
Total Other Income/Expenses Net-46,895-16,873
 

Technical Analysis of 10X Genomics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of 10X Genomics Inc. The general trend of 10X Genomics Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine 10X Genomics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of 10X Genomics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 40.51 < 41.23 < 48.42.

The bearish price targets are: 34.19 > 33.79 > 31.28.

Tweet this
10X Genomics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of 10X Genomics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

10X Genomics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of 10X Genomics Inc. The current macd is -2.30033181.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the 10X Genomics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for 10X Genomics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the 10X Genomics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
10X Genomics Inc Daily Moving Average Convergence/Divergence (MACD) Chart10X Genomics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of 10X Genomics Inc. The current adx is 26.03.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell 10X Genomics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
10X Genomics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of 10X Genomics Inc. The current sar is 39.14.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
10X Genomics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of 10X Genomics Inc. The current rsi is 34.24. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
10X Genomics Inc Daily Relative Strength Index (RSI) Chart10X Genomics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of 10X Genomics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the 10X Genomics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
10X Genomics Inc Daily Stochastic Oscillator Chart10X Genomics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of 10X Genomics Inc. The current cci is -70.45580878.

10X Genomics Inc Daily Commodity Channel Index (CCI) Chart10X Genomics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of 10X Genomics Inc. The current cmo is -30.88328294.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
10X Genomics Inc Daily Chande Momentum Oscillator (CMO) Chart10X Genomics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of 10X Genomics Inc. The current willr is -79.78580991.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that 10X Genomics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
10X Genomics Inc Daily Williams %R Chart10X Genomics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of 10X Genomics Inc.

10X Genomics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of 10X Genomics Inc. The current atr is 1.70006366.

10X Genomics Inc Daily Average True Range (ATR) Chart10X Genomics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of 10X Genomics Inc. The current obv is -26,170,239.

10X Genomics Inc Daily On-Balance Volume (OBV) Chart10X Genomics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of 10X Genomics Inc. The current mfi is 32.74.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
10X Genomics Inc Daily Money Flow Index (MFI) Chart10X Genomics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for 10X Genomics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

10X Genomics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of 10X Genomics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.238
Ma 20Greater thanMa 5039.448
Ma 50Greater thanMa 10042.837
Ma 100Greater thanMa 20044.919
OpenGreater thanClose36.880
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of 10X Genomics Inc with someone you think should read this too:
  • Are you bullish or bearish on 10X Genomics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about 10X Genomics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about 10X Genomics Inc

I send you an email if I find something interesting about 10X Genomics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about 10X Genomics Inc.

Receive notifications about 10X Genomics Inc in your mailbox!